Skip navigation

neuroinfuse™ drug delivery system

Novel chronic and acute catheter systems for direct delivery of therapeutics to the brain

Crossing the blood-brain barrier

Intraparenchymal drug delivery offers a practical method of bypassing the blood-brain barrier (BBB) and shows great promise in providing the next step change in the treatment of neurodegenerative, neuro oncology and other debilitating neurological conditions.

We are developing a patented range of engineering solutions to cover chronic (long term) implantable and acute (short term) implantable intraparenchymal drug delivery. Our low dead volume chronic device has a novel, MRI compatible, transcutaneous port that aims to provide a solution for simultaneous intermittent drug delivery to the central nervous system (CNS) through multiple catheters (up to four) at any time interval.

Watch an introductory video

A complete robotic platform

Features and benefits

Feature

Benefit
Implantation performed outside of MRIReduces the burden on costly MRI equipment and radiologists
MRI compatibleEnables real-time imaging of infusions
Acute infusionsSuitable for one-off infusions, catheter can be explanted after use
Chronic infusionsEnables repeated infusions and flexible administration regimes
Patient specificCatheter length can be adjusted to encourage custom therapy distribution
4-channel re-accessible catheter system with independent fluid paths and flow ratesAllows the clinician to control and customise the therapy
regime
Repeat administrations do not require additional surgeryReduces inherent risk of repeated surgery
Repeated delivery of fixed volumesAims to deliver consistent and repeatable treatment
Outpatient infusionsReduces strain on in-patient facilities

Working with clinical partners

Over several years Renishaw has been working with experienced clinical experts to produce a specification for an intraparenchymal drug delivery device and stereotactic delivery platform that facilitates convection enhanced delivery (CED) and other infusion applications.

The chronic product is currently undergoing clinical investigation as part of the Horizon 2020 funded TreatER project. TreatER is a first-in-human clinical study examining the intraparenchymal delivery of CDNF for the treatment of Parkinson's disease.

Drug development opportunities

The development team behind the neuroinfuse drug delivery system has considerable experience investigating CED. By using our products and engaging with our engineers as early as possible, pharmaceutical partners can help ensure new therapies suitable for intraparenchymal delivery are translated into clinical practice as smoothly as possible. Testing the drug and delivery method in combination enables product trouble-shooting to take place well in advance of clinical investigation. As uncertainty is addressed and risk reduced at each development stage, this collaborative approach provides investors and pharmacological experts with the confidence required to move in to subsequent translational stages.

Potential applications

 Gene therapyCellsDrugsProteinsEnzymes
Acute ♦
Chronic ♦

At present, the Renishaw neuroinfuse drug delivery system can only be used in the setting of an approved clinical trial. Renishaw is currently seeking academic, clinical and commercial partners across a wide range of indications, from oncology to neurodegenerative diseases. The purpose of this website is only to obtain partners and not to make the device generally available.

Downloads